A paucimorphic variant in the HMG-CoA reductase gene is associated with lipid-lowering response to statin treatment in diabetes: A GoDARTS study

Pharmacogenetics and Genomics

Volumn 18, Issue 12, 2008, Pages 1021-1026

  Donnelly, Louise A ^c   Doney, Alex S F ^a   Dannfald, Jennifer ^b   Whitley, Adrian L ^b   Lang, Chim C ^a   Morris, Andrew D ^a   Donnan, Peter T ^d   Palmer, Colin N A ^b,e  

^a Department of Medicine   (United Kingdom)

^b NINEWELLS HOSPITAL   (United Kingdom)

^c Division of Community Health Sciences

^d UNIVERSITY OF DUNDEE   (United Kingdom)

^e UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

3 Hydroxy 3 methylglutaryl coenzyme A reductase; Diabetes mellitus; Lipoproteins; Statins

Indexed keywords

ATORVASTATIN; CERIVASTATIN; CHOLESTEROL; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; DRUG ACTIVITY; FEMALE; GENE; GENETIC VARIABILITY; GENOTYPE; HMGCR GENE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN FUNCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

COHORT STUDIES; DIABETES MELLITUS; FEMALE; GENOTYPE; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPIDS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 57149124098     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e3283106071     Document Type: Article

References (35)

1. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. Lancet 2001; 357:995-1001.
2. Mangravite LM, Krauss RM. Pharmacogenomics of statin response. Curr Opin Lipidol 2007; 18:409-414.
3. Kuivenhoven JA, Jukema JW, Zwinderman AH, de Knijff P, McPherson R, Bruschke AV, et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. N Engl J Med 1998; 338:86-93.
4. Ordovas JM, Lopez-Miranda J, Perez-Jimenez F, Rodriguez C, Park JS, Cole T, et al. Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG CoA reductase inhibitor therapy. Atherosclerosis 1995; 113:157-166.
5. Nestel P, Simons L, Barter P, Clifton P, Colquhoun D, Hamilton-Craig I, et al. A comparative study of the efficacy of simvastatin and gsmfibrozil in combined hyperlipoproteinemia: prediction of response by baseline lipide, apo E genotype, lipoprotein (a) and insulin. Atherosclerosis 1997; 129:231-239.
6. Ballantyne CM, Herd JA, Stein EA, Ferlic LL, Dunn JK, Gotto AM, et al. Apolipoprotein E genotypes and response of plasma lipids and progression-regression of coronary atherosclerosis to lipid-lowering drug therapy. J Am Coll Cardiol 2000; 36:1572-1578.
7. Pedro-Botet J, Schaefer EJ, Bakker-Arkema RG, Black DM, Stein EM, Corolla D, et al. Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner. Atherosclerosis 2001; 158:183-193.
8. Ojala JP, Helve E, Ennholm C, Aalto-Setala K, Kontula KK, Tikkanen MJ. Effect of apolipoprotein E polymorphism and Xbal polymorphism of apolipoprotein B on response to lovastatin treatment in familial and non-familial hypercholesterolaemia. J Intern Med 1991; 230:397-405.
9. Guzman EC, Hirata MH, Quintao EC, Hirata RD. Association of the apolipoprotein B gene polymorphisms with cholesterol levels and response to fluvastatin in Brazilian individuals with high risk for coronary heart disease. Clin Chem Lab Med 2000; 38:731-736.
10. van Venrooij FV, Stolk RP, Banga JD, Sijmonsma TP, van Tol A, Erkelens DW, et al. Common cholesteryl ester transfer protein gene polymorphisms and the effect of atorvastatin therapy in type 2 diabetes. Diabetes Care 2003; 26:1216-1223.
11. Donnelly LA, Palmer CNA, Whitley AL, Lang CC, Doney ASF, Morris AD, et al. Apolipoprotein E genotypes are associated with lipid-lowering response to statin therapy in diabetes: a Go-DARTS study. Pharmacogenet Genomics 2008; 18:279-287.
12. Ness GC, Chambers CM. Feedback and hormonal regulation of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase: the concept of cholesterol buffering capacity. Exp Biol Med 2000; 224:8-19.
13. Chasman DI, Posada D, Subrahmanyan L, Cook NR, Stanton Jr V, Ridker PM. Pharmacogenetic study of statin therapy and cholesterol reduction. J Am Med Assoc 2004; 291:2821-2827.
14. Grundy SM, Pasternak R, Greenland P, Smith Jr S, Fuster V. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for Healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 1999; 100:1481-1492.
15. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16:434-444.
16. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hyperchotesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333:1301-1307.
17. Scandinavian Simvastatin Study (4S). Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383-1389.
18. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Eng J Med 1996; 336:1001-1009.
19. The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Eng J Med 1998; 339:1349-1357.
20. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. J Am Med Assoc 1998; 279:1615-1622.
21. Costa J, Borges M, David C, Camerio AV. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomized controlled trials. Br Med J 2006; 332:1115-1124.
22. Morris AD, Boyle DIR, MacAlpine R, Emslie-Smith A, Jung RT, Newton RW, et al. The diabetes audit and research in Tayside Scotland (DARTS) study: electronic record linkage to create a diabetes register. DARTS/MEMO Collaboration. Br Med J 1997; 315:524-528.
23. Evans JMM, McDevitt DG, MacDonald TM. The Tayside Medicines Monitoring Unit (MEMO): a record-linkage system for pharmacovigilance. Pharmaceut Med 1995; 9:177-184.
24. British Medical Association and Royal Pharmaceutical Society of Great Britain. British National Formulary 2003; London: BMJ Books.
25. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18:499-502.
26. Donnan PT, MacDonald TM, Morris AD. Adherence to prescribed oral hypoglycaemic medication in a population of patients with Type 2 diabetes: a retrospective cohort study. Diabet Med 2002; 19:279-284.
27. Pearson ER, Donnelly LA, Kimber C, Whitley A, Doney AS, McCarthy MI, et al. Variation in TCF7L2 influences therapeutic response to sulfonylureas: a GoDARTs study. Diabetes 2007; 56:2178-2182.
28. JBS 2. Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Prepared by: British Cardiac Society, British Hypertension Society, Diabetes UK, HEART UK, Primary Care Cardiovascular Society, Stroke Association. Heart 2005; 91:1-52.
29. Hilleman D, Wurdeman RL, Lenz TL Therapeutic change of HMG-CoA reductase inhibitors in patients with coronary artery disease. Pharmacotherapy 2001; 21:410-415.
30. Schafer JL, Graham JW. Missing data: Our view of the state of the art. Psychological Methods 2002; 7:147-177.
31. Institute S. SAS/Stat 9.1 User's Guide: SAS Publishing, 2004.
32. Thompson JF, Man M, Johnson KJ, Wood LS, Lira ME, Lloyd DB, et al. An association study of 43 SNPs in 16 candidate genes with atorvastatin response. Pharmacogenomics J 2005; 5:352-358.
33. Singer JB, Holdaas H, Jardine AG, Fellstrøm B, Os I, Bermann G, et al. Investigators AoLiRTAS. Genetic analysis of fluvastatin response and dyslipidemia in renal transplant recipients. J Lipid Res. 2007; 48:2072-2078.
34. Krauss RM, Mangravite LM, Smith JD, Medina MW, Wang D, Guo X, et al. Variation in the 3-hydroxyl-3-methylglutaryl coenzyme a reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment. Circulation 2008; 117:1537- 1544.
35. Polisecki E, Muallem H, Maeda N, Peter I, Robertson M, McMahon AD, et al. Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER. Atherosclerosis 2008; 200:109-114.